- Table of Contents
We validate the specificity of these antibodies to Protein S100-A13 by testing them on tissues known to express S100A13 positively and negatively. Browse below to find the S100A13 antibody that suites your experiment. We have 5 of these antibodies and many publications and validation images.
If you cannot find antibodies that fit your needs, contact us for making custom antibodies. We have a full suite of custom antibody services covering from research to diagnostic and therapeutic applications.
Facts about Protein S100-A13.
Binds one copper ion. Binding of a single copper ion does not interfere with calcium binding.
S100 calcium binding protein A13; S100 calcium-binding protein A13protein S100-A13; S100A13
|Sequence:||1; NC_000001.11 (153618799..153634361, complement)|
Expressed in heart and skeletal muscle.
Cytoplasm. Secreted. Secretion is mediated by exposure to stress and requires copper ions.
If you are interested to acquire this antibody, you will probably want more information about Steven Boster and his history. Continue reading to find out more about Boster, his bio, and the applications of the product. You might also want to take a look at the company application information. Boster Bio: Best Uses of The S100A13 Marker Specimens & Applications guide is also available. This guide provides useful tips and tricks on how to use the antibody in specific situations.
Boster bio's Anti-S100A Monoclonic Anti-S100A (Melanocytic Cell Marker), S100A1 monoclonic Anti-S100A1 monoclonic Antibody is non-hazardous. It is stable for up-24 months. It can be purchased either with or without BSA. Blocking of peptides at 1.0mg/ml is available at a cost which varies with the immunogen duration. Boster Bio validates its antibody against known positive and/or negative samples.
The S100 protein family consists of 21 members. The S100A1-S100B proteins are calcium binding proteins that dissolve in 100% saturated ammonium sulfurate. Moore observed that S100A1 (and S100B) were both soluble in the exact same solution in 1965. Many members of the family cluster on human DNA chromosomes 1, 4 and 5, and are distributed on chromosomes 4, 5 and 6.
S100A proteins can mediate inflammatory responses in cancer, autoimmune disease, and chronic inflammatory diseases. S100-neutralizing antibodies may offer a novel therapeutic strategy, according molecular analysis. Studies on S100 antibodies have indicated efficacy in several diseases, including hematological cancers and autoimmune and inflammatory disorders.
The anti-S100A (Melanomama Marker) S100A1 mono-clonal antibody from Boster Bio is highly specific to S100A. It can activate CD8 T cells directly to respond to tumors. It is therefore very effective in melanoma research. The results are encouraging and patients should consider clinical trials.
Its mechanism of operation is unknown. However, small molecule inhibitors are available. It is believed that the S100 protein interacts strongly with small molecules, which in turn inhibit its binding. These unique surface geometries play an important role in the selectivity and specificity of these molecules. S100A is more selective than S100A.
This monoclonal antibody is highly specific and can effectively inhibit S100A in cancer research. The antibodies have shown anti-tumor activity in murine models and in humans. They have also been shown to be anti-inflammatory in murine models of colon inflammation. Monoclonal anti-inflammatory antibodies are also useful in reducing inflammation, preserving bone and collagen, and other functions.
Several non-covalent S100 inhibitors have been identified. These include paquinimod (ABR-215757) and tasquinimod (ABR-215050). Both S100 proteins have different TFP-binding pockets, which make them difficult to inhibit. These compounds could have limited effectiveness in treating certain cancers.
FDA has approved MK-3475 by the company. This drug is an important part the ongoing Phase II trials. It is being investigated for its use in the treatment of melanoma and other solid tumours. It is considered a good option for patients with advanced disease. It is available as a variety of forms.
The immunotherapy is effective for patients with advanced melanomas. It targets tumor-mediated immune suppression and increases anti-tumor immune responses. Combinations of immunotherapy (CTLA-4 and PD-1) are proving to be effective in the treatment of advanced melanoma patients. They can also be used in the treatment for refractory and advanced melanoma.
You've reached the right place if you're curious about Steve Boster's current location. We have all the details about Steve Boster, from his past addresses and current addresses to his phone number and email addresses. You can also find out if Steve has any relatives. We can search his public records by state and age, and find out what his friends and family think of him. Below are a few resources that will help you learn more about Steve Boster.
Steve Boster's life began in Joliet IL. He was the son of James and Evelyn Meier Boster. He worked in the retail business all his life, and was a Concordia Hall Member in Staunton. He is survived by his two daughters, Natosha and Crystal Boster, as well as 6 grandchildren. His brothers and sisters are David Boster, Sandra Blanton, and Jack Boster. His nieces & nephews also survived him.
The S100A13 mark is a novel marker for angiogenic proteins. Its expression is reduced in HCC tissues and high levels are associated with favorable survival. It was found to play an important role in stress-induced FGF-1 export. However, it is not clear what its exact role is. The applications of the S100A13 marker are only beginning to be explored. Here are some key findings. These findings are listed below:
First, this protein is highly expressed in melanocytic and other lesions. Second, it is thought to play a key role in the development new blood vessels. It is believed that it may work in concert with VEGFA to promote tumor growth. S100A13 is associated with melanoma relapse rates in a positive way. Although more research is needed to fully understand S100A13's expression in melanoma patients, these preliminary findings suggest S100A13 might be an angiogenic marker that can be used to diagnose tumors.
Another study found S100A13 to be upregulated in HCC and para-tumor tissues. Interestingly, S100A14 mRNA expression was found to be associated with poor prognosis. S100A13 expression has also been associated with low-grade, or melanoma-like, glioma. S100A13 expression can be used as a biomarker for many inflammatory conditions.
S100A13 has a dual role in cell-growth regulation. In the intracellular region, it inhibits cell growth, while in the extracellular space, it promotes cell growth. In addition, S100A13 promotes migration and invasion of HCC cells. It has been linked to poor survival rates in bladder cancer. It also promotes an aggressive phenotype in lung carcinoma-derived cell liners. S100A13, therefore, is a promising biomarker of lung cancer.